Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Ferry

Showing results (111-120 of 125) with videos related to

Pageof 13
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 4, 2000
A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpointsD R Ferry, M Deakin, J Baddeley, et al.
Thorax|September 13, 2008
Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancerS M Lee, L E James, W Qian, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 23, 1999
Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamineP J Julyan, L W Seymour, D R Ferry, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2017
A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplificationE Van Cutsem, Y-J Bang, W Mansoor, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2013
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trialJosep Tabernero, Eric Van Cutsem, Radek Lakomý, et al.
Cancer Chemotherapy and Pharmacology|May 4, 2018
Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancerEgbert F Smit, Edward B Garon, Martin Reck, et al.
The New England Journal of Medicine|June 19, 1998
Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial InvestigatorsW E Boden, R A O'Rourke, M H Crawford, et al.
Lancet (London, England)|July 17, 2007
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trialMatthew T Seymour, Timothy S Maughan, Jonathan A Ledermann, et al.
International Journal of Oncology|May 9, 2009
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancerLeonard W Seymour, David R Ferry, David J Kerr, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2014
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapyPaul Ruff, David R Ferry, Radek Lakomỳ, et al.
Pageof 13

Showing results (111-120 of 125) with videos related to

Sort By:
Pageof 13
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 4, 2000
A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpointsD R Ferry, M Deakin, J Baddeley, et al.
Thorax|September 13, 2008
Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancerS M Lee, L E James, W Qian, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 23, 1999
Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamineP J Julyan, L W Seymour, D R Ferry, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2017
A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplificationE Van Cutsem, Y-J Bang, W Mansoor, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2013
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trialJosep Tabernero, Eric Van Cutsem, Radek Lakomý, et al.
Cancer Chemotherapy and Pharmacology|May 4, 2018
Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancerEgbert F Smit, Edward B Garon, Martin Reck, et al.
The New England Journal of Medicine|June 19, 1998
Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial InvestigatorsW E Boden, R A O'Rourke, M H Crawford, et al.
Lancet (London, England)|July 17, 2007
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trialMatthew T Seymour, Timothy S Maughan, Jonathan A Ledermann, et al.
International Journal of Oncology|May 9, 2009
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancerLeonard W Seymour, David R Ferry, David J Kerr, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2014
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapyPaul Ruff, David R Ferry, Radek Lakomỳ, et al.
Pageof 13